Xeris Biopharma
Xeris Biopharma's revenue rose 43.7% to $292 million in fiscal 2025. Its operating margin was 8.5%, up from −16.6% a year earlier. The diluted share count rose 17.7%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Xeris Biopharma does
Xeris Biopharma is a pharmaceutical company that develops and sells treatments for long-term hormone and nerve disorders in the United States. It sells three medicines. Recorlev treats high cortisol levels in adults with Cushing's syndrome when surgery is not an option or has not cured it. Gvoke is a ready-to-use liquid glucagon for severe low blood sugar in people with diabetes age two and older. Keveyis treats primary periodic paralysis, a rare genetic disorder that can cause extreme muscle weakness.
The company earns its revenue from selling these three products. It calls maximizing them its top priority.
Its main product in development is XP-8121, a once-weekly injection under the skin of levothyroxine, a thyroid hormone, for hypothyroidism. Xeris says it plans to start a Phase 3 trial in 2026. The name Xeris comes from a Greek word meaning dry. It uses its own non-water-based drug formulations, XeriSol and XeriJect, to make drugs that can be injected, and it is looking for partners that would use that technology on other companies' drugs.
Its biggest risks, as it describes them
- A limited history of selling drugs and large losses since it began.
- It may need more capital, which could dilute shareholders or not be available.
- Cash may not be enough to pay interest and principal on its debt.
- Its business depends on the commercial success of its products and candidates.
- Competition, and needing strong sales, marketing and distribution to sell its medicines.
Income statement
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 102 | 122 | 72 | 72 | 111 |
| Debt incl. finance leases | 88 | 187 | 191 | 232 | 220 |
| Net debt (negative means net cash) | −14 | 65 | 118 | 160 | 109 |
| Net debt to EBITDA | — | — | — | — | 4.2x |
| Debt to equity | 0.9x | 4.1x | — | — | — |
| Interest coverage | −16.0x | −5.8x | −1.6x | −1.1x | 0.9x |
| Current ratio | 1.8x | 2.5x | 1.6x | 1.7x | 2.2x |
| Quick ratio | 1.6x | 2.2x | 1.2x | 1.2x | 1.6x |
Cash flow
Projections
Project Xeris Biopharma's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 14, 2025 and November 13, 2026, no insider bought Xeris Biopharma shares on the open market, and 9 insiders sold $4.7 million, $3.7 million of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 28, 2026 | Kevin McCullochSee Remarks | Sold plan | 25,000 | $10.00 | $250,000 | Form 4 |
| Sep 1, 2026 | Beth HechtSee Remarks | Sold plan | 16,666 | $8.49 | $141,494 | Form 4 |
| Sep 1, 2026 | Kevin McCullochSee Remarks | Sold plan | 15,000 | $8.49 | $127,350 | Form 4 |
| Sep 1, 2026 | Steven PieperSee Remarks | Sold plan | 5,000 | $8.50 | $42,500 | Form 4 |
| Aug 12, 2026 | Steven PieperSee Remarks | Sold plan | 5,000 | $8.50 | $42,500 | Form 4 |
| Aug 3, 2026 | Beth HechtSee Remarks | Sold plan | 16,666 | $8.01 | $133,495 | Form 4 |
| Aug 3, 2026 | Kevin McCullochSee Remarks | Sold plan | 15,000 | $8.02 | $120,300 | Form 4 |
| Jul 7, 2026 | Steven PieperSee Remarks | Sold plan | 27,600 | $8.52 | $235,152 | Form 4 |
| Jul 6, 2026 | Steven PieperSee Remarks | Sold plan | 17,400 | $8.50 | $147,900 | Form 4 |
| Jul 1, 2026 | Kevin McCullochSee Remarks | Sold plan | 90,000 | $8.03 | $722,700 | Form 4 |
| Jul 1, 2026 | Beth HechtSee Remarks | Sold plan | 16,666 | $8.03 | $133,828 | Form 4 |
| Jun 4, 2026 | Dawn HalkuffDirector | Sold plan | 20,000 | $6.09 | $121,800 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 4 of 8 | 4 of 8 | 7 of 8 |
| Rule of 40 | — | — | — |
| Altman Z'' | −5.93 | −6.20 | −2.99 |
| Accruals ratio | −4.6% | −5.5% | −8.0% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Pass |
| Cash from operations is positive | Fail | Fail | Pass |
| Return on assets rose | Pass | Pass | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Pass | Fail | Pass |
| Current ratio rose | Fail | Pass | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Pass | Pass | Pass |
| F-score | 4 of 8 | 4 of 8 | 7 of 8 |
Compare
Put Xeris Biopharma side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Xeris Biopharma | FY25 | 43.7% | 8.5% | — | 19.6% | 4.2x | 7 | |
| Rigel Pharmaceuticals | FY25 | 64.2% | 42.6% | — | 91.3% | −0.8x | 7 | Compare |
| Ironwood Pharmaceuticals | FY25 | −15.7% | 33.3% | 42.9% | — | — | — | Compare |
| Evolus | FY25 | 11.6% | −11.0% | −15.4% | −47.2% | — | 2 | Compare |
| Aurinia Pharmaceuticals | FY25 | 20.4% | 37.1% | 47.8% | — | — | — | Compare |
6 years of figures
| Fiscal year | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Income statement | ||||||
| Revenue | 20 | 50 | 110 | 164 | 203 | 292 |
| Revenue growth | — | 142.7% | 122.3% | 48.7% | 23.9% | 43.7% |
| Gross profit | — | — | — | — | — | — |
| Research and development | 21 | 25 | 21 | 22 | 26 | 31 |
| Operating income | −84 | −115 | −82 | −44 | −34 | 25 |
| Net income | −91 | −123 | −95 | −62 | −55 | 1 |
| Diluted EPS (US$) | −2.14 | −1.55 | −0.70 | −0.45 | −0.37 | 0.00 |
| Diluted shares (millions) | 43 | 79 | 136 | 138 | 147 | 173 |
| Cash flow | ||||||
| Cash from operations | −81 | −96 | −103 | −47 | −37 | 29 |
| Capital expenditure | 0 | 1 | — | — | — | — |
| Free cash flow | −81 | −97 | — | — | — | — |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 8 | 11 | 12 | 11 | 18 | 22 |
| Balance sheet at fiscal year end | ||||||
| Cash and short-term investments | 134 | 102 | 122 | 72 | 72 | 111 |
| Debt incl. finance leases | 87 | 88 | 187 | 191 | 232 | 220 |
| Total assets | 159 | 304 | 344 | 323 | 323 | 384 |
| Total liabilities | 125 | 209 | 299 | 329 | 353 | 370 |
| Shareholders' equity | 34 | 95 | 45 | −7 | −30 | 14 |
| Margins and ratios | ||||||
| Gross margin | — | — | — | — | — | — |
| Operating margin | −408.8% | −232.2% | −74.3% | −26.9% | −16.6% | 8.5% |
| Net margin | −446.0% | −247.5% | −85.9% | −38.0% | −27.0% | 0.2% |
| Free cash flow margin | −396.1% | −194.8% | — | — | — | — |
| Rule of 40 (growth + FCF margin) | — | −52.2% | — | — | — | — |
| Return on capital | — | −268.1% | −67.7% | −31.3% | −21.9% | 19.6% |
| Return on equity | — | −190.3% | −134.8% | −324.2% | — | — |
| Return on assets | — | −53.0% | −29.2% | −18.7% | −17.0% | 0.2% |
| Net debt to EBITDA | — | — | — | — | — | 4.2x |